The analysis of patients’ survival in association with the CD133 score revealed a mean OS of 37.91 ± 17.18 months for patients with low CD133 tumor expression and 36.96 ± 19.40 months for patients with high CD133 tumor expression. The gene discussed is PROM1; the disease is neoplasm.